PRINCETON, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy ...

Clinical Strategy Summary Announced activation of the first site in March 2025 Trial designed to include approximately 350 patients PDS Biotech is aligned with the U.S. Food and Drug ...